Literature DB >> 19372454

Different clinical phenotypes in monozygotic CADASIL twins with a novel NOTCH3 mutation.

Kati Mykkänen, Maija Junna, Kaarina Amberla, Lena Bronge, Helena Kääriäinen, Minna Pöyhönen, Hannu Kalimo, Matti Viitanen.   

Abstract

BACKGROUND AND
PURPOSE: CADASIL is a hereditary arteriopathy causing recurrent strokes and cognitive decline. Because monozygotic twins have identical genetic background, differences in their environment and lifestyle could reveal factors that may influence CADASIL patients' clinical course, which is highly variable even within the same family.
METHODS: We describe differences in clinical and imaging findings in a pair of monozygotic CADASIL twins.
RESULTS: Twin B experienced his first-ever stroke 14 years earlier than twin A, and his symptoms, signs, and imaging findings were more severe. Distinguishing factors were twin B's smoking as well as twin A's physical activity and earlier statin treatment. Causative NOTCH3 mutation was a novel c.752G>A -substitution (p.Cys251Tyr).
CONCLUSIONS: The phenotypic differences in these monozygotic twins suggest influence of environmental and lifestyle factors on the clinical course of CADASIL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19372454     DOI: 10.1161/STROKEAHA.108.528661

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  9 in total

Review 1.  New information on the genetics of stroke.

Authors:  James F Meschia
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

2.  CADASIL in central Italy: a retrospective clinical and genetic study in 229 patients.

Authors:  Silvia Bianchi; Enza Zicari; Alessandra Carluccio; Ilaria Di Donato; Francesca Pescini; Serena Nannucci; Raffaella Valenti; Michele Ragno; Domenico Inzitari; Leonardo Pantoni; Antonio Federico; Maria Teresa Dotti
Journal:  J Neurol       Date:  2014-10-26       Impact factor: 4.849

3.  Parkinsonism in a pair of monozygotic CADASIL twins sharing the R1006C mutation: a transcranial sonography study.

Authors:  Michele Ragno; Sandro Sanguigni; Antonio Manca; Luigi Pianese; Cristina Paci; Alfonso Berbellini; Valeria Cozzolino; Roberto Gobbato; Silvio Peluso; Giuseppe De Michele
Journal:  Neurol Sci       Date:  2016-02-05       Impact factor: 3.307

4.  Electrophilic and Drug-Induced Stimulation of NOTCH3 N-terminal Fragment Oligomerization in Cerebrovascular Pathology.

Authors:  K Z Young; N M P Cartee; S J Lee; S G Keep; M I Ivanova; Michael M Wang
Journal:  Transl Stroke Res       Date:  2021-05-03       Impact factor: 6.829

5.  Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy in an Israeli family.

Authors:  Radi Shahien; Silvia Bianchi; Abdalla Bowirrat
Journal:  Neuropsychiatr Dis Treat       Date:  2011-06-20       Impact factor: 2.570

6.  Impairments in Episodic-Autobiographical Memory and Emotional and Social Information Processing in CADASIL during Mid-Adulthood.

Authors:  Angelica Staniloiu; Friedrich G Woermann; Hans J Markowitsch
Journal:  Front Behav Neurosci       Date:  2014-06-25       Impact factor: 3.558

Review 7.  Clinical and Genetic Aspects of CADASIL.

Authors:  Toshiki Mizuno; Ikuko Mizuta; Akiko Watanabe-Hosomi; Mao Mukai; Takashi Koizumi
Journal:  Front Aging Neurosci       Date:  2020-05-07       Impact factor: 5.750

Review 8.  Recurrent generalized seizures as the prominent manifestation in a patient with CADASIL: a case report and literature review.

Authors:  Liuhua Pan; Yan Chen; Shanshan Zhao
Journal:  BMC Neurol       Date:  2022-09-30       Impact factor: 2.903

9.  Naturally occurring NOTCH3 exon skipping attenuates NOTCH3 protein aggregation and disease severity in CADASIL patients.

Authors:  Gido Gravesteijn; Johannes G Dauwerse; Maurice Overzier; Gwendolyn Brouwer; Ingrid Hegeman; Aat A Mulder; Frank Baas; Mark C Kruit; Gisela M Terwindt; Sjoerd G van Duinen; Carolina R Jost; Annemieke Aartsma-Rus; Saskia A J Lesnik Oberstein; Julie W Rutten
Journal:  Hum Mol Genet       Date:  2020-07-21       Impact factor: 6.150

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.